CJC-1295/Ipamorelin
A synergistic peptide combination for optimized, sustained growth hormone release.
From $279/mo
How It Works
CJC-1295 binds to GHRH receptors on anterior pituitary somatotroph cells, activating the Gs/cAMP/PKA signaling pathway to stimulate GH gene transcription and secretion. The DAC (Drug Affinity Complex) modification enables covalent albumin binding, extending the half-life to 6-8 days and providing continuous low-level GHRH receptor stimulation. Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a) through a separate mechanism, amplifying GH pulse amplitude. Crucially, GHS-R1a activation sensitizes somatotrophs to GHRH signaling, creating a synergistic effect - the CJC-1295 stimulus produces a larger GH response when ipamorelin is present. Unlike hexarelin or GHRP-6, ipamorelin does not significantly increase cortisol, prolactin, or appetite hormones at therapeutic doses, making it the most selective GHS-R1a agonist available. The combined effect increases GH pulse amplitude by 2-3x and total daily GH secretion by approximately 200-300% above baseline.
Key Benefits
Clinical Research
Pharmacokinetic studies of CJC-1295 with DAC demonstrated a 2-10 fold increase in mean GH levels sustained for 6+ days after a single injection, with IGF-1 levels increasing 1.5-3x above baseline and remaining elevated for 9-11 days (Teichman et al., 2006). Ipamorelin studies showed dose-dependent GH release with a 30-minute peak, without clinically significant changes in cortisol, prolactin, FSH, LH, or TSH (Raun et al., 1998). The combination has been studied in age-related GH decline, showing restoration of youthful GH pulsatility patterns. A study by Ionescu and Frohman (2006) demonstrated that concurrent GHRH and GHS-R agonism produces supra-additive GH release in humans. Clinical use data from regenerative medicine practices report improvements in IGF-1 levels, body composition, sleep quality, and recovery markers over 3-6 month treatment periods.
Dosage & Administration
Dosage
Common protocols include CJC-1295 with DAC at 1-2 mg administered once or twice weekly via subcutaneous injection, combined with ipamorelin at 200-300 mcg administered subcutaneously 1-3 times daily (typically at bedtime). An alternative protocol uses CJC-1295 without DAC (also called Mod GRF 1-29) at 100-200 mcg combined with ipamorelin 200-300 mcg, both injected together 1-3 times daily. The DAC version requires less frequent dosing but produces more constant GH elevation, while the non-DAC version produces more pulsatile, physiological release patterns. Your GetPepWell physician will select the protocol best suited to your goals.
Administration
Both peptides are administered as subcutaneous injections. The CJC-1295 with DAC component is typically injected 1-2 times per week in the abdominal area. Ipamorelin is injected 1-3 times daily, with the most important dose being 30-60 minutes before bedtime on an empty stomach (no food for 2+ hours). Some protocols mix both peptides in the same syringe for convenience. Use 29-31 gauge insulin syringes and rotate injection sites. Avoid eating for at least 30 minutes after injection, as insulin suppresses GH release. The combination is often cycled 5 days on, 2 days off, or used continuously for 3-6 months followed by a 1-month break.
Side Effects
- Injection site reactions (redness, minor swelling)
- Headache, especially during the first 1-2 weeks
- Flushing or warmth after injection
- Water retention (mild, usually transient)
- Increased hunger (less common than with GHRP-6)
- Tingling or numbness in extremities (sign of elevated GH)
- Vivid dreams and deeper sleep (generally considered positive)
Contra-indications
- Active malignancy or history of cancer
- Known hypersensitivity to either peptide or excipients
- Pituitary disorders or tumors
- Uncontrolled diabetes (GH can worsen insulin resistance)
- Pregnancy or breastfeeding
- Active diabetic retinopathy
- Untreated hypothyroidism
Drug Interactions
- Glucocorticoids - may blunt the GH response; timing adjustments may help
- Insulin - GH elevation can increase insulin resistance; monitor glucose
- Somatostatin analogs (octreotide) - directly antagonize GH release; do not combine
- Other GH secretagogues - additive effects may cause excessive GH stimulation
- Thyroid medications - adequate thyroid function required for optimal GH synthesis
Storage Info
Store both peptides as lyophilized powder refrigerated at 36-46 degrees F (2-8 degrees C). After reconstitution with bacteriostatic water, store refrigerated and use within 30 days. CJC-1295 with DAC is more stable than the non-DAC version. Do not freeze reconstituted solutions. Protect from light and heat. Gently swirl when reconstituting.
CJC-1295/Ipamorelin FAQ
Find answers to the most common questions about this treatment.
Related Products
Interested in CJC-1295/Ipamorelin?
Schedule a consultation with a licensed physician to see if this treatment is right for you.